Release Date: December 8, 2025
Expiration Date: December 8, 2026
Activity Overview
C3 glomerulopathy (C3G) is a rare, complement-mediated kidney disease characterized by abnormal activation of the complement system, resulting in excessive deposition of the complement protein C3 in the glomeruli and subsequent inflammation and injury. To address unmet needs and education gaps, this online activity features international clinician-researchers discussing the latest insights in C3G, including best practices in diagnosis and emerging approaches to treatment. The activity will also feature a firsthand perspective from a patient living with the condition, offering clinicians a deeper understanding of its real-world impact.
Target Audience
This educational activity is directed toward nephrologists, nephrology nurses, renal dieticians, primary care providers, NPs, PAs, RNs, and other health care professionals involved in the care of patients with C3G.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Review the clinical burden of C3G on patient QOL and health outcomes
- Identify the appropriate imaging and testing modalities for the diagnosis of C3G subtypes
- Analyze the safety and efficacy of targeted agents for C3G
- Design individualized management plans for patients with C3G
Jonathan Barratt, PhD, FRCP
Professor of Renal Medicine
University of Leicester
Honorary Consultant Nephrologist
The John Walls Renal Unit, Leicester
Leicester, England
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Alnylam Pharmaceuticals, Argenx, Astellas Pharma, BioCryst Pharmaceuticals, Calliditas Therapeutics, Chinook Therapeutics, Dimerix, Galapagos, Novartis Pharmaceuticals Corporation, Omeros Corporation, Travere Therapeutics, Vera Therapeutics, Visterra Inc; Grant/Research Funding: Argenx, Calliditas Therapeutics, Chinook Therapeutics, Galapagos, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Omeros Corporation, Travere Therapeutics, Visterra Inc
Brendon L. Neuen, MBBS, PhD, MSc
Associate Professor of Medicine
Program Lead, Renal and Metabolic, The George Institute for Global
Health
Director of Kidney Trials, Royal North Shore Hospital
Sydney, Australia
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Alexion Pharmaceuticals, AstraZeneca, Bayer AG, Boehringer Ingelheim, Cornerstone Medical Education, CSL Behring, CSL Seqirus, EMedscape, the Limbic, Novo Nordisk, Otsuka Pharmaceutical Co, Travere Therapeutics, Vera Therapeutics; Grant/Research Funding: Bayer AG, Boehringer Ingelheim, Menarini Group
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only. It is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here